Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (ISRCTN14917997) titled 'Prevention of childhood asthma using house dust mite allergen tablets' on Sept. 11.
Study Type: Interventional
Study Design:
Interventional double blind randomized parallel group placebo controlled trial (Safety, Efficacy)
Primary Sponsor: University of Southampton
Condition:
Paediatric asthma
Respiratory
Intervention:
Active intervention: Acarizax (12 SQ-HDM SLIT). Control: Placebo. Dose: 30 µg. Dose frequency: Once daily. Route of administration: Sublingual. All infants will be reviewed every 6 weeks by telephone/video call, in the first year and then every 3 months. The researchers will be contacta...